AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05408286 — intervention group
Intervention type: BEHAVIORAL
Intervention: administration of questionnaires
Description: administration of questionnaires
Study NCT04750005 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Listerine Cool Mint
Description: Participants use 20 mL of Listerine cool mint mouth rinse for 30 sec after brushing twice a day.
Study NCT04750005 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Colgate Cavity Protection Toothpaste
Description: Participants used Colgate cavity protection toothpaste for brushing teeth twice daily.
Study NCT04750005 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Colgate Cavity Protection Toothpaste
Description: Participants used Colgate cavity protection toothpaste for brushing teeth twice daily.
Study NCT04750005 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reach Unflavored Waxed Dental Floss
Description: Participants after brushing for 1 minute, rinse mouth with water and FLOSS once a day in first use.
Study NCT04750005 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: American Dental Association (ADA) Ref Toothbrush
Description: Participants will brush twice daily for 1 minute with the toothpaste and soft bristled toothbrush provided.
Study NCT04750005 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: American Dental Association (ADA) Ref Toothbrush
Description: Participants will brush twice daily for 1 minute with the toothpaste and soft bristled toothbrush provided.
Study NCT03081715 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PD-1 Knockout T Cells
Description: Programmed cell death 1(PD-1) gene will be knocked out by CRISPR Cas9
Study NCT02618564 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sennosides
Description: Each group will be assigned different doses of sennosides and varying times of administration
Study NCT01029678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin IV
Description: Cisplatin IV 30 mg/m2/ (Day 1, Day 8, Day 15, Day 22, Day 29, Day 36)
Study NCT01029678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Vinorelbine per os 30 mg/m2/(day1, day8, day15, day22, day29, day36
Study NCT01029678 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 66Gy, 33 fractions, 6 week
Study NCT04383340 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Standard hospital care and parental support
Study NCT03738098 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Participants will receive traditional genetic counseling (GC) for the Baseline and Return of Results (ROR1) visits.
Study NCT03738098 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Participants will receive traditional genetic counseling (GC) for the Baseline and Return of Results (ROR1) visits.
Study NCT03738098 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GUÍA
Description: GUÍA for the ROR1 visit.
Study NCT00143598 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Knee-length, graduated elastic compression stocking
Description: Worn daily for 2 years, 30-40 mm Hg
Study NCT00143598 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Knee-length, placebo stocking
Description: Worn daily for two years
Study NCT00801086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 7% (w/v) Tempol alcohol-based gel (MTS-01)
Description: 200mL gel applied daily prior to radiation dose and removed immediately thereafter.
Study NCT00801086 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: alcohol-based gel
Description: 200mL gel applied daily prior to radiation dose and removed immediately thereafter
Study NCT01907217 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ECT Mecta 5000M
Description: ECT is administered twice weekly with hand-held electrodes using the Mecta 5000M device following a standard stimulus dosing protocol. Seizure duration is measured by EEG monitoring. Methohexitone (0.75-1.0 mg/kg) is used for anaesthesia with suxamethonium (0.5-1.0 mg/kg) as muscle relaxant. Seizure threshold (ST) is established by a method of limits at the first session and subsequent treatments will be given at 1.5 x ST for BT ECT and 6.0 x ST for RUL ECT. To reflect routine clinical practice, number of ECT treatments is determined by referring physicians who will be blind to randomisation. The treatment period varies between patients to allow up to 12 administrations of ECT, i.e. up to 6 weeks.
Study NCT01907217 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECT Mecta 5000M
Description: ECT is administered twice weekly with hand-held electrodes using the Mecta 5000M device following a standard stimulus dosing protocol. Seizure duration is measured by EEG monitoring. Methohexitone (0.75-1.0 mg/kg) is used for anaesthesia with suxamethonium (0.5-1.0 mg/kg) as muscle relaxant. Seizure threshold (ST) is established by a method of limits at the first session and subsequent treatments will be given at 1.5 x ST for BT ECT and 6.0 x ST for RUL ECT. To reflect routine clinical practice, number of ECT treatments is determined by referring physicians who will be blind to randomisation. The treatment period varies between patients to allow up to 12 administrations of ECT, i.e. up to 6 weeks.
Study NCT01907217 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methohexitone
Description: Methohexitone (0.75-1.0 mg/kg) is used for anaesthesia along with suxamethonium (0.5-1.0 mg/kg)for muscle relaxation. Anesthesia is the same for both arms of the trial.
Study NCT01907217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methohexitone
Description: Methohexitone (0.75-1.0 mg/kg) is used for anaesthesia along with suxamethonium (0.5-1.0 mg/kg)for muscle relaxation. Anesthesia is the same for both arms of the trial.
Study NCT01907217 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Suxamethonium
Description: Suxamethonium (0.5-1.0 mg/kg)is used for muscle relaxation along with Methohexitone (0.75-1.0 mg/kg) for anaesthesia. Anesthesia is the same for both arms of the trial.
Study NCT01907217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suxamethonium
Description: Suxamethonium (0.5-1.0 mg/kg)is used for muscle relaxation along with Methohexitone (0.75-1.0 mg/kg) for anaesthesia. Anesthesia is the same for both arms of the trial.
Study NCT03484221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI
Description: IRINOTECAN 150 mg/m\^2 IV over 1-h, day 1 + OXALIPLATIN 85 mg/m\^2 IV over 2-h, day 1 + L-LEUCOVORIN 200 mg/m\^2 IV over 2-h, day 1 + 5-FLUOROURACIL 2800 mg/m\^2 IV 48-h continuous infusion, starting on day 1 administered every two weeks for 4 cycles (2 months).
Study NCT03484221 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Short-Course Radiation Therapy(5Gy*5)
Description: Patients received a short-course radiation therapy(5Gy\*5) after 4 cycles of FOLFOXIRI.
Study NCT03484221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XELOX
Description: OXALIPLATIN 130 mg/m\^2 IV over 2-h, day 1 Capecitabine 1000 mg/m\^2 twice daily days 1-14 every 3 weeks for 4 cycles.
Study NCT04407416 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Breath sampling
Description: The breath of all subjects included will be sampled using a device able to capture the alveolar air and to fix it on carbon tubes, Then the tubes will be desorbed and analysed using gas chromatography
Study NCT05196906 — intervention group
Intervention type: PROCEDURE
Intervention: Modified Broström operation and anatomic reconstruction operation
Description: Patients with CLAI and GJL will accept the Modified Broström operation or anatomic reconstruction operation.
Study NCT03324828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyzine
Description: Hydroxyzine solution
Study NCT03324828 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyzine
Description: Hydroxyzine solution
Study NCT03324828 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clowns intervention
Description: Clowns intervention
Study NCT00434577 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Herpes Zoster vaccine GSK1437173A Low Dose
Description: Single or two-dose intramuscular injection.
Study NCT00434577 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Herpes Zoster vaccine GSK1437173A Medium Dose
Description: Single or two-dose intramuscular injection.
Study NCT00434577 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Herpes Zoster vaccine GSK1437173A High Dose
Description: Single or two-dose intramuscular injection.
Study NCT00434577 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Herpes Zoster vaccine GSK1437173A High Dose
Description: Single or two-dose intramuscular injection.
Study NCT03324828 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clowns intervention
Description: Clowns intervention
Study NCT00975858 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronary Revascularization
Description: revascularization of coronary arteries in case of symptomatic obstructive coronary artery disease
Study NCT00434577 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Herpes Zoster vaccine GSK1437173A Modified
Description: Single or two-dose intramuscular injection.
Study NCT00434577 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single intramuscular injection
Study NCT02082418 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alpha-lactalbumin
Description: Subjects will ingest the liquid meal containing alpha-lactalbumin and carbohydrates (0.6 g/kg FFM protein + 0.3 g/kg FFM carbohydrates).
Study NCT02082418 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey
Description: commercially available whey protein
Study NCT02082418 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Casein
Description: commercially available casein protein
Study NCT00975858 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary Revascularization
Description: revascularization of coronary arteries in case of symptomatic obstructive coronary artery disease
Study NCT02846935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: 2-4 capsules depending on the weight of participant. Dec capsules are ingested \~60 minutes after THU capsules.
Study NCT02846935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrahydrouridine
Description: 2-4 capsules depending on the weight of participant. Oral THU capsules followed 60 minutes later by oral Dec capsules are ingested 2X/week on consecutive days.
Study NCT01232569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab 162 mg
Description: Tocilizumab will be supplied in a ready-to-use, single-use, pre-filled syringe. Patients and/or caregivers will be trained to administer the injection.
Study NCT01232569 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be supplied in a ready-to-use, single-use, pre-filled syringe. Patients and/or caregivers will be trained to administer the injection.
Study NCT04210375 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JK07
Description: Recombinant fusion protein consisting of a fully humanized immunoglobulin G1 monoclonal antibody and an active polypeptide fragment of the human growth factor NRG-1
Study NCT04210375 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Vehicle control
Study NCT01542034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deoxycholic acid injection
Description: Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.
Study NCT01542034 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Phosphate buffered saline placebo for injection
Study NCT02804906 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based physical therapy
Description: Participants will be visited by a physical therapist 3 times a week for approximately 1 hour each day, for a duration of 4 weeks. These visits will serve to encourage adherence to the intervention, reinforce activities recommended at discharge, monitor safety under direct supervision, and adjust the exercise prescription if/as needed (e.g. advance recommended activity level) if necessary. Patients will also be provided with a tablet computer device installed with software, Moving Analytics, that will reinforce the cardiac rehabilitation program through daily reminders and easily accessible visual activity plans. This program will be updated by the physical therapist during home visits as the program advances. Daily patient-reported health status (Your Activities of Daily Living) 26 will be ascertained on the same tablet device by participants three times per week using open source software designed.
Study NCT02804906 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants in the control arm will be provided with a 30-minute counseling session on risk factor modification prior to discharge. Participants will be provided with a tablet computer device to complete patient-reported health status (Your Activities of Daily Living) 26 three times per week using open source software designed. Participants will be visited by the Research Coordinator or member of the study team at one month post-hospital discharge to perform a follow-up assessment that will include ADLs, IADLs, SF-12 PCS, frailty measures, and questions on healthcare utilization (hospital readmissions).
Study NCT03118791 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: anthocyanins
Description: Acute intake of capsules
Study NCT03118791 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: anthocyanins
Description: Acute intake of capsules
Study NCT01578954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Reinduction/Consolidation - dose escalation of lenalidomide: Level 1 - 25mg, Level 2 - 35mg, Level 3 - 50mg, PO, QD, 28 days.~Maintenance Lenalidomide - 10mg, PO, QD, continuous dosing, 12 months
Study NCT04291677 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intervention musical
Description: Intervention group in which musical intervention will be applied the first or third day of mechanical ventilation.
Study NCT04291677 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Without intervention musical
Description: Control group with standard treatment without musical intervention.
Study NCT03203460 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-intensity aerobic interval training (HIIT)
Description: A 12-week, supervised, HIIT aerobic exercise program consisting of alternating vigorous- and low-intensity intervals
Study NCT00248976 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Net-present value of individual health behaviors in years
Study NCT01778647 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Stimulants plus Lovaza
Description: Patients randomized to stimulants plus Lovaza (Omega-3 fatty acids). Treated and evaluated for up to 16 weeks. Conners and CGI scales filled out by parents, teachers and evaluators on each visit
Study NCT01778647 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Stimulants plus placebo
Description: Patients randomized to usual dose of stimulants plus placebo. Patients evaluated for up to 16 weeks. Conners rating scales and CGI filled out by evaluators, parents and teachers.
Study NCT01488838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin: 40 mg/m2 weekly during radiation
Description: Cisplatin: 40 mg/m2 weekly during radiation for 7 doses
Study NCT01488838 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation: 60-66 Gy in 2 Gy daily fractions
Description: Radiation: 60-66 Gy in 2 Gy daily fractions
Study NCT04237519 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SFL training
Description: The SFL training program comprises:~* Physical exercises: 50 video exercises to improve balance, muscle strength and physical capabilities in older adults;~* Cognitive exercises: Four ludic activities targeting problem solving (4 Images/ 1 word), memory (Quiz and Recall me), speed processing and divided attention (Attention!).~In addition, the SFL program includes a series of unique components:~* Chat rooms: to share views about topics of interest and tips for common real-life problems;~* Psycho-education content: to improve self-management and promoting cognitive transfer though 22 different topics (provide recommendations usually given in psychotherapy sessions);~* Virtual coach: to guide participants along the proposed exercises by giving them instructions, reminding them regularly to practice a variety of available activities repeatedly, providing appropriate and timely feedback on participant's performances and rewarding assiduity, perseverance and performance.
Study NCT04237519 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active controlled training
Description: The active control training program is structured in the same manner as the SFL training program and will also offer different physical and cognitive activities:~* Physical exercises: 12 different exercises trains upper and lower extremity strength, mobility and balance offered through a computerized version of a health insurance company physical training program;~* Cognitive activities: Four commercially available leisure activities (Sudoku. Cross Words, Pac-Man and Countdown activities) that are appreciated by older adults but do not teach cognitive strategies and are were not designed to improve cognition per se.~No chat room, psycho-educational content or virtual coach were included in the active control training program.
Study NCT01281215 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education interventional
Description: The patients will receive pharmaceutical education to know more about asthma, the importance of treatment compliance, the medications used to control the pathology, corrected patients' inhalation techniques and the medication care.
Study NCT01195740 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attachment Based Family Therapy
Description: ABFT has three phases. In phase one, treatment focuses on helping the adolescent identify past and present family conflicts that have strained the attachment bond and damaged trust. Adolescents and parents are taught new communication and affect regulation skills in preparation for reparative conversations in phase two. This phase of treatment involves adolescents and parents discussing these past and present conflicts using their new communication skills. The final phase of treatment focuses on promoting adolescent autonomy (i.e., improving school productivity, finding a job, etc.). For the suicidal/depressed adolescent, this can decrease isolation and increase exposure to positive experiences. To accomplish these goals, there are five ABFT treatment tasks. Each task may take one or several sessions. Youth randomized to this condition will receive approximately 14 weeks of ABFT. One orientation meeting will occur, whenever possible, on the inpatient unit prior to discharge.
Study NCT03283059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octohydroaminoacridine Succinate
Description: Octohydroaminoacridine Succinate Tablet:4mg P.O. tid
Study NCT03283059 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aricept
Description: Aricept 5mg/day, P.O.
Study NCT03283059 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo Tablet: P.O. tid
Study NCT03342131 — intervention group
Intervention type: OTHER
Intervention: Circulating wnt 2 and wnt 4 concentration
Description: Blood (150 each group) is obtained into ethylenediaminetetraacetic acid（EDTA） tubes from all subjects via antecubital venepuncture to explore circulating wnt 2 and wnt 4 concentration by ELISA. Continuous wnt2 and wnt4 concentration are measured in all patients with STEMI at 0 , 7days and 12 months after admission. Other patients with acute syndrome system are measured Wnt 2 and wnt4 only once within 24h after admission.~Wnt2 and wnt4 concentration in Control group will be measured only once with 24h after admission.
Study NCT01706575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon (Peginterferon) Alfa-2a
Description: Peginterferon alfa-2a 180 mcg, subcutaneously (SC) once weekly for 48 weeks.
Study NCT01706575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nucleos(t)ide Analogues (NA)
Description: Nucleos(t)ide analogues includes adefovir, entecavir, lamivudine or tenofovir.
Study NCT03215719 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Standard Radiation Treatment
Description: An interval scan at 4 weeks to assess for a good response defined as >40% nodal shrinkage will stratify patients into receiving standard treatment (≤40% nodal shrinkage) or a dose-deescalated treatment regimen (>40% nodal shrinkage). Those with nodal shrinkage and clearance of circulating plasma HPV DNA shall undergo further treatment de-escalation.
Study NCT03215719 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Dose-Deescalated Treatment
Description: Intensity-modulated radiation therapy (IMRT) is an advanced type of radiation therapy used to treat cancer and noncancerous tumors. IMRT uses advanced technology to manipulate photon and proton beams of radiation to conform to the shape of a tumor. Patients will be treated with intensity-modulated radiation therapy (IMRT) with megavoltage photons
Study NCT03215719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatinum
Description: Standard of care chemotherapy